Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Mar;38(3):309-318.
doi: 10.1002/phar.2083. Epub 2018 Feb 23.

Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease

Maxwell D Anderegg  1 , Tyler H Gums  2 , Liz Uribe  3 , Eric J MacLaughlin  4 , James Hoehns  1   5 , Oralia V Bazaldua  6 , Timothy J Ives  7 , David L Hahn  8 , Christopher S Coffey  3 , Barry L Carter  1   9
Affiliations
Randomized Controlled Trial

Pharmacist Intervention for Blood Pressure Control in Patients with Diabetes and/or Chronic Kidney Disease

Maxwell D Anderegg et al. Pharmacotherapy. 2018 Mar.

Abstract

Objectives: The objectives of this study were to determine if hypertensive patients with comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) receiving a pharmacist intervention had a greater reduction in mean blood pressure (BP) and improved BP control at 9 months compared with those receiving usual care; and compare Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guideline and 2014 guideline (JNC 8) BP control rates in patients with DM and/or CKD.

Methods: This cluster randomized trial included 32 medical offices in 15 states. Clinical pharmacists made treatment recommendations to physicians at intervention sites. This post hoc analysis evaluated mean BP and BP control rates in the intervention and control groups.

Main results: The study included 335 patients (227 intervention, 108 control) when mean BP and control rates were evaluated by JNC 7 inclusion and control criteria. When JNC 8 inclusion and control criteria were applied, 241 patients (165 intervention, 76 control) remained and were included in the analysis. The pharmacist-intervention group had significantly greater mean systolic blood pressure reduction compared with usual care at 9 months (8.64 mm Hg; 95% confidence interval [CI] -12.8 to -4.49, p<0.001). The pharmacist-intervention group had significantly higher BP control at 9 months than usual care by either the JNC 7 or JNC 8 inclusion and control groups (adjusted odds ratio [OR] 1.97, 95% CI 1.01-3.86, p=0.0470 and OR 2.16, 95% CI 1.21-3.85, p=0.0102, respectively).

Principal conclusions: This study demonstrated that a physician-pharmacist collaborative intervention was effective in reducing mean systolic BP and improving BP control in patients with uncontrolled hypertension with DM and/or CKD, regardless of which BP guidelines were used.

Trial registration: ClinicalTrials.gov NCT00935077.

Keywords: chronic kidney disease; diabetes; hypertension; team-based care.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Authors of this paper have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this manuscript.

Figures

Figure 1
Figure 1
CONSORT Statement of Clinic Randomization and Patient Participation CONSORT: Consolidated Standards of Reporting Trials BP: Blood pressure DM: Diabetes mellitus CKD: Chronic kidney disease
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. High Blood Pressure Fact Sheet. Centers for Disease Control and Prevention; [Accessed on December 20, 2017]. [cited 2016 July 14]. Available from: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_bloodpressure.htm.
    1. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999–2013 on CDC WONDER Online Database, released 2015. [Accessed on December 20, 2017];Data are from the Multiple Cause of Death Files, 1999–2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http://wonder.cdc.gov/ucd-icd10.html.
    1. Vinik A, Flemmer M. Diabetes and macrovascular disease. Journal of diabetes and its complications. 2002;16(3):235–45. - PubMed
    1. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Annals of internal medicine. 1996;124(1 Pt 2):90–6. - PubMed
    1. Daly C. Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007;22(Suppl 9):ix19–25. - PubMed

Publication types

Associated data